You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨石藥集團(1093.HK)漲4.56%市值重回千億港元 抗腫瘤藥獲內地臨牀試驗
格隆匯 05-20 13:49
格隆匯5月20日丨石藥集團(1093.HK)午後漲幅擴大至4.56%,報16.5港元,暫成交5.3億港元,最新總市值1029億港元。石藥集團19日宣佈,公司附屬公司石藥集團中奇製藥技術(石家莊)有限公司開發的"注射用多西他賽(白蛋白結合型)"已獲中國國家藥品監督管理局批准可以在中國開展臨牀試驗。預期該產品極有希望在臨牀研究中展現出良好的抗腫瘤治療效果,力爭該產品儘快上市。另外,本月初附屬公司治療肝病藥物獲批,為國內該品種第三家獲批的仿製藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account